Wedbush Remains Bullish on Clearside Biomedical (CLSD) Following Annual ASRS Meeting Presentation

August 15, 2016 8:02 AM EDT
Get Alerts CLSD Hot Sheet
Price: $8.81 --0%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 12 | New: 41
Trade CLSD Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Wedbush reiterated an Outperform rating and $28.00 price target on Clearside Biomedical (NASDAQ: CLSD) as the company presents follow-on results from its trials of Zuprata. During the Q&A presenters answered questions about improved safety including: the lack of elevated IOP, lack of hemorrhage, and lack of cataracts.

Analyst Liana Moussatos commented, "Dr. Steven Yeh (Emory University), Dr. Seenu Hariprasad (University of Chicago) and Dr. Shree Kurup will be giving oral presentations on data from Clearside’s Phase 2 (DOGWOOD) and Phase 1/2 trials. Abstracts for the presentations are currently embargoed; however, we anticipate results to corroborate previously released positive topline Phase 2 data reported in early January. Recall the Phase 2 trial met its primary endpoint of improvement from baseline in central subfield thickness at eight weeks after a single injection of Zuprata (p=0.0018) and improvement in best-corrected visual acuity (p=0.0004), an important secondary endpoint. We look to the presentations for additional data pointing to further improvement in inflammation, including reduction in anterior chamber cells and chamber flare, and improvement in vitreous haze."

For an analyst ratings summary and ratings history on Clearside Biomedical click here. For more ratings news on Clearside Biomedical click here.

Shares of Clearside Biomedical closed at $7.19 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Liana Moussatos

Add Your Comment